Product References — Pooled Human Complement Serum

Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles

Posted by Adam Awdish on

Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles

Pooled Human AB Serum Off The Clot from Innovative Research was used in the following study:   Effects of Different Separation Methods on the Physical and Functional Properties of Extracellular Vesicles Hyungtaek Jeon, Su-Kyung Kang, Myung-Shin Lee PLoS ONE July 7, 2020 Extracellular vesicles (EVs) are nano-sized membrane vesicles (20–500 nm) of endocytic origin that are secreted by most cells under normal physiological conditions, as well as by cells undergoing pathological processes. EVs contain a variety of molecules such as proteins, nucleic acids, and lipids, which are affected by environmental factors and health conditions, making them potential biomarkers for diseases...

Read more →

Trimethylamine N-oxide–derived zwitterionic polymers: A new class of ultralow fouling bioinspired materials

Posted by Corey Marcath on

Trimethylamine N-oxide–derived zwitterionic polymers: A new class of ultralow fouling bioinspired materials

Pooled Human Complement Serum from Innovative Research was used in the following study:   Trimethylamine N-oxide–derived zwitterionic polymers: A new class of ultralow fouling bioinspired materials Bowen Li, Priyesh Jain, Jinrong Ma, Josh K. Smith, Zhefan Yuan, Hsiang-Chieh Hung, Yuwei He, Xiaojie Lin, Kan Wu, Jim Pfaendtner, and Shaoyi Jiang Science Advances 2019 Jun 14 ”…Materials that resist nonspecific protein adsorption are needed for many applications. However, few are able to achieve ultralow fouling in complex biological milieu. Zwitterionic polymers emerge as a class of highly effective ultralow fouling materials due to their superhydrophilicity, outperforming other hydrophilic materials such as...

Read more →

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica Lukmanee Tradtrantip, Tianjiao Duan, Michael R. Yeaman, Alan S. Verkman Journal of Neuroinflammation December 2019, 16:57 "... Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility...

Read more →

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Posted by Leanne Kodsmann on

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Human Complement from Innovative Research was used in the following study:   Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica Tianjiao Duan, Alex J. Smith and Alan S. Verkman Journal of Neuroinflammation, October 2018 "... Specified concentrations of AQP4-IgG (or control human IgG, Thermo Fisher Scientific, Rockford, IL) and human complement (Innovative Research, Novi, MI) were added in Hank’s buffer, and cells were incubated at 37 °C for specified times. In some experiments, cells were exposed to serum of an AQP4-IgG seropositive NMO patient who met the revised diagnostic criteria for clinical disease. A fixable dead-cell stain (amine-reactive dye,...

Read more →

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Posted by Leanne Kodsmann on

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Human Complement Serum from Innovative Research was used in the following study:   Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo Experimental Hematology & Oncology, October 2018 "... Complement-rich human serum (CRHS) was from Innovative Research (Novi, MI), was aliquoted, cryopreserved and thawed for immediate use. For CDC studies, cells were aliquoted at 4 × 105 per well,...

Read more →